Royal Philips launches AI-focused incubator program

Danielle Brown | | Health Exec | Artificial Intelligence

Health technology company Royal Philips has launched its global incubator program for startup companies looking to apply artificial intelligence (AI)-based solutions into healthcare.

The company announced the launch of the program on Tuesday, Oct. 16. The 12-week program will feature 19 different AI startup companies from 14 different countries. The incubator will focus on the application of AI in healthcare, and more specifically, on the application of AI-based clinical decision support tools. The startups were chosen from 750 applicants.

Philips plans to work with each company in “validating their propositions, helping to build, test and scale their ideas, and exploring possible collaborations.”

“We are already working closely with clinical partners to develop AI-enabled solutions that are grounded in scientific research and validated in clinical practice,” Philips Healthworks Head Alberto Prado said in a statement. “This new collaboration program recognizes the role that start-up companies play in bringing breakthrough healthcare innovations to the market.”

""
Danielle Brown

Danielle covers Clinical Innovation & Technology as a senior news writer for TriMed Media. Previously, she worked as a news reporter in northeast Missouri and earned a journalism degree from the University of Illinois at Urbana-Champaign. She's also a huge fan of the Chicago Cubs, Bears and Bulls. 

Related Content

AI model gets helpful heart assessments out of nongated CT scans
3 points to ponder before tapping AI for mental healthcare
Global market researchers: ‘Build a culture that uses healthcare AI to uplift human potential’
A symbiosis observed: How AI is refining the savviness of the e-patient
Research review: Patients have understandably mixed feelings about AI in healthcare
5 attributes every AI system will soon need to make hay in healthcare

Around the web

Cardiovascular Business
Eli Lilly to acquire gene-editing specialists focused on CVD for up to $1.3B

The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

Cardiovascular Business
AMA House of Delegates helps cardiology groups influence healthcare policies

American College of Cardiology Board of Governors Chair David E. Winchester, MD, MS, examines the many benefits of working with the American Medical Association House of Delegates to bring about significant change.

Cardiovascular Business
Smaller revenues, less growth: In US, tariffs may create headaches for $34.5B cardiovascular device market

“Without a more concrete and stable policy on these tariffs from the current American administration, it is likely that most manufacturers will be forced to continuously change their internal forecasts and production plans," one analyst said.